A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)
Latest Information Update: 05 Jun 2020
At a glance
- Drugs Crizanlizumab (Primary)
- Indications Vaso-occlusive crisis
- Focus Therapeutic Use
- Acronyms STAND
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 12 May 2020 Status changed from suspended to recruiting.
- 26 Apr 2020 Status changed from recruiting to suspended.
- 21 Jan 2020 Planned End Date changed from 5 Nov 2027 to 6 Dec 2027.